The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor.
 
Kimberly Mayumi Komatsubara
No Relationships to Disclose
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Castle Biosciences; Immunocore; Vaccinex
Research Funding - Bristol-Myers Squibb; Immunocore
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Sapna Pradyuman Patel
Stock and Other Ownership Interests - Provectus
Honoraria - Dava Oncology; PCME, Rockpointe; PlatformQ Health
Consulting or Advisory Role - Amgen; Genentech/Roche
Speakers' Bureau - Bristol-Myers Squibb (Mexico); Merck
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Prometheus (Inst); Reata Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (Mexico); Merck
 
Parisa Momtaz
No Relationships to Disclose
 
Shahnaz Singh-Kandah
No Relationships to Disclose
 
Amanda Carter
No Relationships to Disclose
 
Suzanne Cain
No Relationships to Disclose
 
Lauren Taiclet
No Relationships to Disclose
 
Sarah DeNoble
No Relationships to Disclose
 
Tiffany Negri
No Relationships to Disclose
 
Danielle Lacey
No Relationships to Disclose
 
Grazia Ambrosini
No Relationships to Disclose
 
Shing Mirn Lee
No Relationships to Disclose
 
Gary K. Schwartz
Honoraria - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics
Consulting or Advisory Role - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology)
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Richard D. Carvajal
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb; Castle Biosciences; Genentech/Roche; Iconic Therapeutics; Janssen Oncology; Merck; Novartis